Published in Neurology on February 01, 1996
Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci (2007) 3.91
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 1.58
The genetics and neuropathology of Alzheimer's disease. Acta Neuropathol (2012) 1.56
Voxel-based morphometry in frontotemporal lobar degeneration with ubiquitin-positive inclusions with and without progranulin mutations. Arch Neurol (2007) 1.39
Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS One (2016) 1.38
Does Alzheimer's disease begin in the brainstem? Neuropathol Appl Neurobiol (2009) 1.26
Light and electron microscopic immunolocalization of presenilin 1 in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal-recessive inclusion-body myopathy. Am J Pathol (1998) 1.00
Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease. Neurotherapeutics (2008) 0.97
Comparison of Abeta levels in the brain of familial and sporadic Alzheimer's disease. Neurochem Int (2009) 0.96
Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography. Sci Rep (2015) 0.89
Does overexpression of betaAPP in aging muscle have a pathogenic role and a relevance to Alzheimer's disease? Clues from inclusion body myositis, cultured human muscle, and transgenic mice. Am J Pathol (1998) 0.87
Amyloid-beta and Alzheimer's disease: the role of neprilysin-2 in amyloid-beta clearance. Front Aging Neurosci (2014) 0.85
Stable size distribution of amyloid plaques over the course of Alzheimer disease. J Neuropathol Exp Neurol (2012) 0.83
Detection of amyloid beta aggregates in the brain of BALB/c mice after Chlamydia pneumoniae infection. Acta Neuropathol (2007) 0.80
Quantitative amyloid imaging using image-derived arterial input function. PLoS One (2015) 0.80
Presenilin/gamma-Secretase and Inflammation. Front Aging Neurosci (2010) 0.79
Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist. Arch Neurol (2008) 0.79
Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study. JAMA Neurol (2016) 0.75
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A (1993) 15.04
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature (1995) 13.80
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature (1975) 10.33
Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol (2001) 9.96
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology (1992) 9.30
Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet (1998) 7.26
Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci (1996) 7.19
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet (1994) 7.07
Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol (1999) 6.98
Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science (1984) 6.86
A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2001) 6.78
Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med (2000) 6.72
Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol (2000) 6.40
Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay. N Engl J Med (1969) 6.15
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A (1998) 6.13
Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol (1997) 6.12
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol (1997) 6.02
A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med (1992) 5.93
Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol (1998) 5.93
Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci U S A (1991) 5.78
Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 5.68
Statins and the risk of dementia. Lancet (2000) 5.65
The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex (1992) 5.57
Internists' and surgeons' attitudes toward guns and firearm injury prevention. Ann Intern Med (1998) 5.15
Support for new policies to regulate firearms. Results of two national surveys. N Engl J Med (1998) 5.06
Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 4.86
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2000) 4.85
Plasma digoxin concentrations in patients with atrial fibrillation. Br Med J (1970) 4.82
Occam's razor, geriatric syndromes, and the dizzy patient. Ann Intern Med (2000) 4.72
MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology (2002) 4.67
Detection of deletions spanning the Duchenne muscular dystrophy locus using a tightly linked DNA segment. Nature (1985) 4.62
Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology (1992) 4.52
Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem (2001) 4.51
APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol (1997) 4.29
Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology (1994) 4.24
Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet (1999) 4.17
Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature (1986) 4.13
Incidence of and risk factors for falls and injurious falls among the community-dwelling elderly. Am J Epidemiol (1993) 4.13
Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet (1997) 4.11
J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. Biochemistry (1991) 4.11
Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol (1996) 4.10
A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science (1991) 4.09
Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology (2004) 4.00
Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA (1997) 4.00
Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J (2006) 3.92
Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron (1993) 3.92
Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci (1999) 3.85
Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts. Mol Psychiatry (2008) 3.68
Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol (1995) 3.60
The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science (1987) 3.59
SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. Am J Hum Genet (2000) 3.58
Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancet (1996) 3.58
Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology (1988) 3.40
A meta-analytic review of research on hostility and physical health. Psychol Bull (1996) 3.27
Digitalis intoxication. A prospective clinical study with serum level correlations. N Engl J Med (1971) 3.27
Apolipoprotein E and Alzheimer's disease. Annu Rev Neurosci (1996) 3.26
Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med (1998) 3.23
Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med (1996) 3.23
Imaging amyloid deposition in Lewy body diseases. Neurology (2008) 3.09
An approach to the dizzy patient. Neurology (1972) 3.06
Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol (2002) 3.02
A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat Genet (1996) 2.98
Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol (1998) 2.92
Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci (1997) 2.91
MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J Biol Chem (2000) 2.83
Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells. J Biol Chem (1996) 2.82
Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder. Nature (1990) 2.80
Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA (2001) 2.79
Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol (2000) 2.78
Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Mol Cell Biol (2001) 2.76
Selective deficits in visual perception and recognition in schizophrenia. Am J Psychiatry (1996) 2.76
Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med (2001) 2.75
FDG PET imaging in patients with pathologically verified dementia. J Nucl Med (2000) 2.70
Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol (1996) 2.68
A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J (2009) 2.66
Digoxin intoxication: the relationship of clinical presentation to serum digoxin concentration. J Clin Invest (1970) 2.66
The distribution of methionine-enkephalin and leucine-enkephalin in the brain and peripheral tissues. Br J Pharmacol (1977) 2.59
Linkage of Charcot-Marie-Tooth neuropathy type 1a to chromosome 17. Exp Neurol (1989) 2.58
Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet (1993) 2.57
Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet (2005) 2.56
BNaC1 and BNaC2 constitute a new family of human neuronal sodium channels related to degenerins and epithelial sodium channels. Proc Natl Acad Sci U S A (1997) 2.53
Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci U S A (1995) 2.53
Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med (1976) 2.49